Trials / Unknown
UnknownNCT03391726
CART-19 Cells for R/R B-cell Lymphoma
CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 1 Year – 65 Years
- Healthy volunteers
- Not accepted
Summary
Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | CART-19 cells | CART-19 cells treat |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2019-12-01
- Completion
- 2020-12-01
- First posted
- 2018-01-05
- Last updated
- 2018-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03391726. Inclusion in this directory is not an endorsement.